Abstract
The objective of our study was to establish whether there is an association between rheumatoid arthritis with extra-articular manifestations (exRA) and anti-cyclic citrullinated peptide 2 (anti-CCP2) antibodies in Greeks. A retrospective study of 220 Greek patients with RA, 95 with exRA and 125 without extra-articular manifestations (cRA). Serum anti-CCP2 antibodies and IgM rheumatoid factor (RF) were measured. CCP2(+) were 65.3% of exRA and 58.4% of cRA patients. RF(+) were 69.5% of exRA and 60.0% of cRA patients. Among exRA patients, 37.9% had high serum anti-CCP2 antibody levels (>100 IU/ml) compared to 21.6% cRA patients (p = 0.008). Serositis and pulmonary fibrosis were found to be associated with high levels of anti-CCP2 antibodies (52.9 vs 26.6%, p = 0.02 and 63.6 vs 26.8%, p = 0.008, respectively). Serum RF levels were 265.0 ± 52.0 IU/ml (mean ± SEM) in exRA and 205.1 ± 40.6 (mean ± SEM) in cRA (NS). High serum RF levels (>268 IU/ml) were more likely to have sicca syndrome. In Greek patients with rheumatoid arthritis (RA), high serum anti-CCP2 antibodies are associated with serositis and pulmonary fibrosis. Therefore, anti-CCP2 antibodies have prognostic significance in patients with RA.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gabriel SE, Crowson CS, Kremers HM et al (2003) Survival in rheumatoid arthritis. A population-based analysis of trends over 40 years. Arthritis Rheum 48:54–8
Ronnelid J, Wick MC, Lampa J et al (2005) Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CCP) during 5 year follow up in early rheumatoid arthritis: anti-CCP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 64:1744–49
Turesson C, Jacobsson LTH, Sturfelt G et al (2007) Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis 66:59–64
van Gaalen FA, van Aken J, Huizinga TWJ et al (2004) Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influence the severity of rheumatoid arthritis. Arthritis Rheum 50:2113–21
Van der Helm-van Mil AH, Verpoort KN, Breedveld FC et al (2006) The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor to develop rheumatoid arthritis. Arthritis Rheum 54:1117–21
Boki KA, Panayi GS, Vaughan RW et al (1992) HLA-class II sequence polymorphisms and susceptibility to rheumatoid arthritis in Greeks. The HLA-DR beta shared epitope accounts for the disease in only a minority of Greeks. Arthritis Rheum 35:749–55
Alexiou I, Germenis A, Ziogas A et al (2007) Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis. BMC Musculoskelet Disord 8:37–43
Zendman AJW, van Venrooij WJ, Pruijn GJM (2006) Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. Rheumatology 45:20–25
Nishimura K, Sugiyama D, Kogata Y et al (2007) Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid a factor for rheumatoid arthritis. Ann Intern Med 146:816–7
De Rycke L, Peene I, Hoffman IEA et al (2004) Rheumatoid factor and anti-citrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 63:1587–93
Korkmaz C, Us T, Kasifoglu T, Akgun Y (2006) Anti-cyclic citrullinated peptide (CCP) antibodies in patients with long-standing rheumatoid arthritis and their relationship with extra-articular manifestations. Clin Biochem 39:961–5
Klareskog L, Stolt P, Lundendberg K et al (2006) A new model for the etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reaction to autoantigens modified by citrullination. Arthritis Rheum 54:38–46
Pedersen M, Jacobsen S, Garred P et al (2007) Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis. A nationwide case-control study in Denmark. Arthritis Rheum 56:1446–53
Stavropoulos C, Spyropoulou M, Koumantaki Y et al (1997) HLA-DRB1* genotypes in Greek rheumatoid arthritis patients: association with disease characteristics, sex and age at onset. Br J Rheumatol 36:141–2
Voskuyl AE, Zwinderman AH, Westedt ML et al (1996) Factors associated with the development of vasculitis in rheumatoid arthritis: results of a case-control study. Ann Rheum Dis 55:190–2
Alessandri C, Bombardieri M, Papa N et al (2004) Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFα therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 63:1218–21
Caramaschi P, Biasi D, Tonolli E et al (2005) Antibodies against cyclic citrullinated peptides in patients with rheumatoid arthritis before and after infliximab treatment. Rheumatol Int 26:58–62
Conflict of interest statement
No conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Alexiou, I., Germenis, A., Koutroumpas, A. et al. Anti-cyclic citrullinated peptide-2 (CCP2) autoantibodies and extra-articular manifestations in Greek patients with rheumatoid arthritis. Clin Rheumatol 27, 511–513 (2008). https://doi.org/10.1007/s10067-007-0800-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-007-0800-1